DD, F1+2 and TAT values at baseline and 4 weeks after discontinuation of VKA, rivaroxaban (R), dabigatran (D) and apixaban (A) VTE treatment. Upper row: increase between baseline and 4 weeks (all significant); lower row: comparison of absolute changes between treatment groups (all not significant)